Transcription

1 National Lung Cancer Audit Frequently Asked Questions What dataset should be used? Please see the LUCADA data manual v3.1.3, available in the downloads section What does LUCADA stand for? LUCADA stands for Lung Cancer Data Who has agreed the outputs and supporting dataset? The NLCA Clinical Reference Group (CRG) identified the priority outputs of the audit. What software is to be used for collecting the LUCADA dataset? The programme has commissioned the development of a web-based (NHSnet) audit IT infrastructure system from the National Health Applications & Infrastructure Services (NHS CFH). What are the security arrangements for LUCADA? Each organisation must first complete a data user certificate, this identifies all users of the system and requires the signature of the Trust Caldicott Guardian. Access to the system is controlled by centrally assigned user names and passwords. The core system uses the same access and security controls as the Open Exeter and CWT systems; named access is over a secure network through the Open Exeter portal Is it possible to upload data to the central database, rather than via the data entry screens? Yes, both CSV and XML file specifications are being developed for upload to the central database.

2 When can an organisation start to use the audit application? As soon as the registration has been processed and a password issued. How long is a password valid for? Passwords expire every 28 days and hence must be changed every 28 days. If a password is not reset within the 28 day window, a call must be logged with the helpdesk who will reset it. If a password it not used for 6 months, the user account expires and a new account must be applied for using the clinical audit form. At what point should the Performance Status be recorded? The Performance Status should be recorded at the point in time closest to the start of treatment. It should be updated if it differs from the original Performance Status entered. Is there a proforma I can use to help me collect the audit data? A proforma is available in the downloads section. As well as the full audit dataset it also highlights the key fields that are essential for the audit. What data should be entered into data field 5.5 (Cancer Care Plan Intent)? There has been uncertainty around the correct interpretation of this field. This is partly due to conflicting data definitions between LUCADA and Cancer Waiting Times and partly due to differences in data definitions between lung cancer and mesothelioma. Data Field 5.5 CANCER CARE PLAN INTENT should be used to record the intention of the treatment which is planned for the patient at this point in time.

3 Intent Plan Details Curative (C) Surgical resection (including open and close' but excluding all surgery on mesothelioma patients) Radical radiotherapy to primary site with potential for cure Chemotherapy in Limited Stage and/or Good Prognosis Small Cell Carcinoma (e.g. using Manchester' prognostic score) Adjuvant (or neo-adjuvant) chemotherapy (combined with surgery) in Non-Small Cell Carcinoma Adjuvant radiotherapy in Small Cell carcinoma Prophylactic Cranial Irradiation Palliative (P) Specialist Palliative Care Chemotherapy in Non-Small Cell Carcinoma (excepting Adjuvant and Neo-adjuvant therapy) Radiotherapy to primary tumour with palliative intent Radiotherapy to site of secondary cancer Brachytherapy (Endobronchial radiotherapy) Other endobronchial treatments (e.g. laser therapy, diathermy, cryotherapy, insertion of bronchial stent) Chemotherapy in Extensive Stage and/or Poor Prognosis Small Cell Carcinoma (e.g. using the Manchester' prognostic score) Surgery for mesothelioma (EPP, debulking surgery and pleurodesis) Surgical Pleurodesis Superior Vena Caval Stenting Palliative - supportive care only (S) This item implies follow up with the aim of identifying symptoms and treating these if and when appropriate. Follow up could be through primary care, secondary care and includes doctors, nurses and Macmillan staff. The plan implies that no immediate treatment is to be given but does not exclude the patient from having treatment at a future date if the need arose. No specific anti-cancer treatment (N) Unknown (9) It is highly unlikely that any treatment plan would be drawn up, where the intention of the treatment is Unknown. The use of this code should be carefully monitored. Important messages: All surgery in mesothelioma patients is to be classified as palliative (P) Pleurodesis, whether medical or surgical, is to be classified as palliative (P)

4 EXAMPLES: 5.5 Scenario C Patient has clinical or histological diagnosis of lung cancer undergoes surgery with curative intent. P Patient has clinical or histological diagnosis of mesothelioma - undergoes EPP, debulking or surgical pleurodesis. P Patient has clinical or histological diagnosis of lung cancer - undergoes surgical or medical pleurodesis. C Patient has clinical or histological diagnosis of lung cancer - undergoes potentially curative chemotherapy and also has surgical or medical pleurodesis. In the latter example, the pleurodesis is recorded as a palliative care intervention in sections L41/L42. What data should be entered into data field L29 (Treatment Planned)? There has been uncertainty around the correct interpretation of these fields. This is partly due to conflicting data definitions between LUCADA and Cancer Waiting Times and partly due to differences in data definitions between lung cancer and mesothelioma. Data Field L29 (TREATMENT PLANNED) should be used to record the type of treatment regimen planned. Code Treatment 01 Surgery For Lung Cancer patients (including clinical diagnoses) - record here any surgical procedure under taken with the intention of curing the patient.do not record here any procedures undertaken for purely diagnostic purposes these should beentered in the Care Plan / MDT section. For Mesothelioma patients - it is accepted that all surgical procedures in this group of patients are palliative. Please enter any therapeutic procedures as surgery other (E57.8). Do not record here any procedures undertaken for purely diagnostic purposes these should be entered in the Care Plan / MDT section. 02 Teletherapy / Radiotherapy

Treatment Algorithms for the Management of Lung Cancer in NSW Guide for Clinicians Background The Cancer Institute New South Wales Oncology Group Lung (NSWOG Lung) identified the need for the development

Lung Cancer Consultant Outcomes Publication Introduction This report describes the outcomes of individual consultant thoracic and cardiothoracic surgeons who carry out surgery for lung cancer. It has been

National Lung Cancer Audit Key findings about the quality of care for people with Lung Cancer in England incorporating headline and completeness data from Wales Report for the audit period 2005 Prepared

Please also see the General Validation Rules tab on the Validation Workbook Question National Oesophago-Gastric Cancer Audit Answer In order to access the data collection system, all users are required

1 Treatment Routes in Prostate Cancer Urological Cancers SSCRG Introduction To better understand outcome measures, it is necessary to analyse what treatment pathway a patient has followed after diagnosis.

Mesothelioma 1. Introduction 1.1 General Information and Aetiology Mesotheliomas are tumours that arise from the mesothelial cells of the pleura, peritoneum, pericardium or tunica vaginalis [1]. Most are

Salisbury Lung Cancer Service (1 of 5) i If you need this information in another language or medium (audio, large print, etc) please contact Customer Care on 0800 374 208 email: customercare@ salisbury.nhs.uk.

Protocol for Planning and Treatment The process to be followed in the management of: SMALL CELL LUNG CANCER Patient information given at each stage following agreed information pathway 1. DIAGNOSIS New

Treatment overview for lung cancer This information is an extract from the booklet Understanding lung cancer. You may find the full booklet helpful. We can send you a free copy see page 5. Contents How

THORACIC ONCOLOGY MULTIDISCIPLINARY TEAM MEETINGS: OPERATIONAL POLICY EXECUTIVE SUMMARY 1. All patients in Lothian with thoracic malignancies should be discussed at designated times in pathway (see App

The treatment you receive will depend on your lung cancer type, for example, whether you have a non-small cell lung cancer Adenocarcinoma or Squamous cell carcinoma, and if this is a sub-type with a mutation.

Lung Cancer Network Group Lung Cancer Awareness Month November 2010 Lung cancer is the leading cause of cancer related death in the Northern Ireland and the UK 1,2. Each year in Northern Ireland approximately

Public Outcomes Report Lung Cancer Submitted by Omar A. Majid, MD Lung cancer is the most common cancer-related cause of death among men and women. It has been estimated that there will be 226,1 new cases

Guideline for the Management of Endometrial Cancer Formerly the Guideline for Post Menopausal Bleeding and Endometrial Cancer Date Approved by Network Governance May 2012 Date for Review May 2015 Changes

National Cancer Waits Project CANCER WAITING TARGETS A GUIDE (VERSION 5) Cancer Action Team Amendments from version 4 to version 5 The waiting times guide has been updated from version 4. Sections which

7. Prostate cancer in PSA relapse A patient with prostate cancer in PSA relapse is one who, having received a primary treatment with intent to cure, has a raised PSA (prostate-specific antigen) level defined

Lung Cancer & Mesothelioma 2011-2015 Annex G Mesothelioma 1. The vision for mesothelioma services is set out in the Mesothelioma Framework issued by DH on 26 February 2007 (supported by the British Thoracic

AA Life Insurance is provided by Friends Life and Pensions Limited What would be the first thing you might think about if you were diagnosed with a serious illness? 2 It is very likely that the first thing

Cancer National Specialist Advisory Group WALES LUNG CANCER DATA REPORT FOR PATIENTS FIRST SEEN BY LUNG CANCER TEAMS IN 2009 AND 2010 Published 2012 Preface The first Wales Lung Cancer Report using prospectively

Updated June 2014 Derived and updated by consensus of members of the Providence Thoracic Oncology Program with the aid of evidence-based National Comprehensive Cancer Network (NCCN) national guidelines,

Oxford University Hospitals NHS Trust Cancer of Unknown Primary (CUP) Information for patients Cancer of unknown primary (CUP) is a term used when cancer has been diagnosed but the original (or primary)

West Midlands Cancer Intelligence Unit Lung Cancer in the West Midlands Supporting the fight against cancer through timely, high quality information provision R11/05 November 2011 0 Author: TE Last updated:

Lung cancer data in the National Cancer Data Repository, Hospital Episode Statistics and National Lung Cancer Audit datasets A comparison of case ascertainment and recording of lung cancer histology and

There are several different kinds of lung cancer, often referred to as lung cancer subtypes. Some of these occur more often than others. In this factsheet we will specifically look at the subtypes of cancers

State of the Nation: An overview of the impact and priorities for lung cancer in Northern Ireland Introduction Lung cancer is Northern Ireland s biggest cancer killer. It causes more than one in five of

Oxford University Hospitals NHS Trust Oxford Lung Cancer and Mesothelioma Multi- Disciplinary Team (MDT) This information leaflet explains the role of the Multi-Disciplinary Team and Specialist Nursing

Lung cancer Understanding NICE guidance information for people with lung cancer, their families and carers, and the public Draft for second consultation September 2004 The paragraphs are numbered for the

Treatment overview for primary bone cancer This information is an extract from the booklet Understanding primary bone cancer. You may find the full booklet helpful. We can send you a free copy see page

Which treatment for advanced lung cancer This information tells you about the treatments for advanced lung cancer. Chemotherapy and radiotherapy can both be used to treat advanced lung cancer. They can

Fighting cancer with information Report series: General cancer information Eastern Cancer Registration and Information Centre ECRIC report series: General cancer information Cancer is a general term for

CLINICAL ONCOLOGY BLUEPRINT OF ASSESSMENT SYSTEM Good Medical Practice areas of curriculum - ST5 (Intermediate) Standards GMP criterion Workplace based assessment By the end of the third year of training

Important information for people with advanced non-small cell lung cancer The following information is only meant for people who have been diagnosed with advanced non-small cell lung cancer (NSCLC). NSCLC

Algorithm for Oesophageal and Gastric Carcinoma (excluding Early Oesophageal and Gastric Cancer/ High Grade Dysplasia) Document Purpose An agreed Network wide pathway for the treatment of patients with

Guideline for the Treatment of Lung Cancer Version History 2.0 Endorsed by the Governance Committee as treatment of lung cancer 27.07.09 with radiotherapy and chemotherapy. 2.1 Re-written to include the

Coversheet for Network Site Specific Group Agreed Documentation This sheet is to accompany all documentation agreed by Pan Birmingham Cancer Network Site Specific Groups. This will assist the Network Governance

About chemotherapy for lung cancer This information is about chemotherapy for lung cancer. There are sections on What is chemotherapy? Chemotherapy for small cell lung cancer Chemotherapy for non-small

REPORT ASCO 2002 ORLANDO : LUNG CANCER Johan F. Vansteenkiste, MD, PhD, Univ. Hospital and Leuven Lung Cancer Group In the 2002 edition of the ASCO meeting, a total of 315 abstracts in the field of respiratory

This resource provides a listing of good quality information, as and when it is needed. Many of the titles listed are available both as publications and as internet downloads; and some also as audio. Please

For customers Friends Life Individual Protection providing access to Best Doctors Access to over 53,000 of the world s leading medical experts, from your first day of cover. A second medical opinion could

Oxford University Hospitals NHS Trust The role of the Specialist Nurse Practitioner for Late Effects Information for patients This leaflet describes the role of the Specialist Nurse Practitioner for Late

Questions to Ask As You Learn More About Kidney Cancer Now that you have been diagnosed with kidney cancer, it is important for you to understand your condition and your treatment options. Many patients

Protocol for Planning and Treatment The process to be followed in the management of: LOCALLY ADVANCED OR METASTATIC RENAL CELL CARCINOMA Patient information given at each stage following agreed information

Deciding what to do about lung cancer This short decision aid is to help you decide what to do about your lung cancer. You can use it on your own, or with your doctor, to help you make a decision about

Types of treatment for breast cancer Useful information for cancer patients Contents This information is about the main treatments used to treat breast cancer. There are sections on The main treatments

Tubular breast cancer This booklet is for people who would like more information about tubular breast cancer. It describes what tubular breast cancer is, its symptoms, how a diagnosis is made and the possible